Edwards Lifesciences Corp (NYSE:EW) VP Larry L. Wood sold 6,300 shares of the firm’s stock in a transaction that occurred on Friday, September 14th. The shares were sold at an average price of $146.95, for a total value of $925,785.00. Following the completion of the sale, the vice president now owns 121,950 shares in the company, valued at $17,920,552.50. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of EW traded down $1.70 during trading hours on Monday, hitting $146.29. 895,300 shares of the company were exchanged, compared to its average volume of 1,287,632. The firm has a market cap of $30.34 billion, a PE ratio of 38.87, a P/E/G ratio of 2.00 and a beta of 0.57. The company has a quick ratio of 1.47, a current ratio of 1.86 and a debt-to-equity ratio of 0.19. Edwards Lifesciences Corp has a one year low of $100.20 and a one year high of $156.87.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 26th. The medical research company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.11. The business had revenue of $972.00 million during the quarter, compared to analyst estimates of $968.32 million. Edwards Lifesciences had a return on equity of 29.11% and a net margin of 19.59%. The company’s revenue was up 10.0% compared to the same quarter last year. During the same period last year, the company posted $1.08 EPS. equities research analysts anticipate that Edwards Lifesciences Corp will post 4.67 EPS for the current fiscal year.

Several brokerages have recently issued reports on EW. BMO Capital Markets lifted their price target on Edwards Lifesciences to $162.00 and gave the company an “outperform” rating in a research report on Tuesday, July 10th. ValuEngine upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Tuesday, June 12th. Royal Bank of Canada lifted their price target on Edwards Lifesciences to $145.00 and gave the company an “outperform” rating in a research report on Wednesday, May 23rd. Northland Securities reiterated a “hold” rating and set a $120.00 price target on shares of Edwards Lifesciences in a research report on Friday, July 27th. Finally, JPMorgan Chase & Co. lifted their price target on Edwards Lifesciences from $133.00 to $150.00 and gave the company a “neutral” rating in a research report on Friday, July 27th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the stock. Edwards Lifesciences currently has a consensus rating of “Buy” and an average target price of $152.45.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. boosted its position in shares of Edwards Lifesciences by 3.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 794,667 shares of the medical research company’s stock worth $115,680,000 after buying an additional 26,346 shares during the period. Summit Global Investments acquired a new stake in shares of Edwards Lifesciences in the second quarter worth $2,923,000. HighPoint Advisor Group LLC boosted its position in shares of Edwards Lifesciences by 38.0% in the first quarter. HighPoint Advisor Group LLC now owns 2,897 shares of the medical research company’s stock worth $414,000 after buying an additional 798 shares during the period. Fulcrum Capital LLC acquired a new stake in shares of Edwards Lifesciences in the second quarter worth $2,920,000. Finally, CIBC Private Wealth Group LLC boosted its position in shares of Edwards Lifesciences by 7.2% in the second quarter. CIBC Private Wealth Group LLC now owns 995,781 shares of the medical research company’s stock worth $144,956,000 after buying an additional 66,544 shares during the period. 82.11% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Featured Article: Stock Symbols and CUSIP Explained

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.